UPDATE: PEI government now covers cancer drug for Valleyfield woman

UPDATE: PEI government now covers cancer drug for Valleyfield woman

After a stressful month spent scrambling to afford thousands of dollars in monthly out-of-pocket drug costs, Melanie Fraser can breathe a sigh of relief. Valleyfield resident Melanie Fraser enjoys the beach with her husband, Robert, in a picture taken several years ago. The 44-year old Valleyfield resident had spoken out publicly to The Guardian in […]

New drug halves hearing loss in children following cancer treatment

New drug halves hearing loss in children following cancer treatment

Giving the drug sodium thiosulphate after chemotherapy reduces hearing loss in children treated for liver cancer, according to findings published in the New England Journal of Medicine today (Wednesday). Results from the Cancer Research UK funded SIOPEL-6 clinical trial show that giving sodium thiosulphate (STS), after a type of chemotherapy called cisplatin, reduces hearing loss […]

Cancer Drug Approvals Are Speedier, But at What Cost?

Cancer Drug Approvals Are Speedier, But at What Cost?

The FDA’s breakthrough therapy designation program has led to faster approval times for cancer drugs but not necessarily better or safer drugs, according to an analysis of recent approvals. A review of cancer drugs approved from 2012 through 2017 showed that drugs receiving breakthrough therapy designation from the FDA reached the market 2 years faster […]

Takeda's CEO on China, Cancer Drugs and Alzheimer's Disease

Takeda's CEO on China, Cancer Drugs and Alzheimer's Disease

Christophe Weber, the first foreign-born chief executive officer of Japan’s Takeda Pharmaceutical Co., last month inked a $62 billion takeover of rare-disease drugmaker Shire Plc. The deal will reshape the 237-old, Osaka-based company into a global powerhouse. In a recent interview in Manhattan, the French-born CEO talked about exciting areas of research and the potential of […]

Breast Cancer Epigenetics Study Reveals Potential Drug Targets

Breast Cancer Epigenetics Study Reveals Potential Drug Targets

Cell lineages that culminate in mammary gland development may also lead to breast cancer. Although these lineages, as well as the stem cells and progenitor cells they comprise, have been subjected to extensive study, the perturbations of these lineages that increase the risk of breast cancer have remained obscure, frustrating the search for chemoprevention drugs. […]

Can-Fite delays phase 2 trial of liver cancer drug Namodenoson

PBR Staff Writer Published 20 June 2018 Israeli biotechnology company Can-Fite BioPharma revealed that the results of its phase 2 trial of its liver cancer drug Namodenoson (CF102) will be delayed longer than originally estimated. However, the company is positive on the outcome of the trial with its final analysis, which is based on survival, […]

Amgen's blood cancer drug gets full EU licence

Amgen's blood cancer drug gets full EU licence

Amgen’s Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy. The company said the European Commission granted the marketing authorisation based on overall survival data from the phase 3 TOWER study, in adults with Philadelphia chromosome-negative […]

Kenya: Cancer Patients Cling on Hope as Drug Runs Out

Kenya: Cancer Patients Cling on Hope as Drug Runs Out

By Elizabeth Merab A group of patients on an expensive breast cancer drug have been forced to delay their treatment after Kenyatta National Hospital (KNH) ran out of the drug four weeks ago. The 81 patients are now clinging onto hope after the Ministry of Health failed to honour its commitment to procure the drug […]

Latecomer Sanofi looks to catch next wave of cancer therapies

Latecomer Sanofi looks to catch next wave of cancer therapies

By Matthias Blamont PARIS (Reuters) – Sanofi <SASY.PA> missed the boat on immune system-boosting cancer drugs. Now it’s trying to catch up. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche <ROG.S> to head its group research operations. And it is now focusing on a pipeline of 10 […]